

A.M.GHELANI & COMPANY

CHARTERED ACCOUNTANTS

AJIT M. GHELANI

B.Com.(Hons),F.C.A,GRAD.C.W.A.

CHINTAN A. GHELANI

B.Com.(Hons),F.C.A,C.S.

To,
The Board of Directors
KILITCH DRUGS (INDIA) LIMITED

LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30.09.2013

1. We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. Kilitch Drugs (India) Limited** for the quarter ended 30th September, 2013, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards notified pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company

Chartered Accountants

(Firm Registration No. 103173)


Chintan A. Ghelani

Partner

Membership No. 104391



Place: Mumbai

Date: 14-11-2013

Enclosed: Unaudited financial results for the quarter ended 30th September, 2013 of
M/s. Kilitch Drugs (India) Limited.

KILITCH DRUGS (INDIA) LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2013
 Regd. Office:- C-30/12, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

PART Sr. No.	Particulars	Three Months Ended		Six Months Ended		Year ended	
		8/30/2013	8/30/2012	9/30/2013	9/30/2012	3/31/2013	3/31/2013
1	Income from operations (a) Net Sales/Income from operations (net of Excise) (b) Other operating income Total Income from Operations (Net)	288.10 66.99 355.09	589.44 0.00 589.44	656.76 66.99 723.75	2070.87 0.00 2070.87	3199.01 119.07 3318.08	
2	Expenses (a) Cost of materials consumed (b) Changes in inventories of finished goods, work-in-progress and stock-in-trade (c) Employee Benefit Expenses (d) Depreciation and Amortisation Expenses (e) Other Expenses Total Expenses	32.55 45.65 63.43 32.78 198.14 372.55	237.67 (44.04) 60.80 33.08 109.52 397.03	406.14 1.61 124.23 65.86 307.66 769.58	1797.58 1.06 119.43 65.62 340.82 2324.51	2659.83 26.13 303.45 122.90 695.89 3808.20	
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	(17.46)	(28.37)	(45.93)	(253.64)	(490.12)	
4	Other Income	99.55	210.52	310.07	584.41	915.05	
5	Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)	82.09	182.15	264.24	330.77	424.93	
6	Finance Costs	(6.18)	6.18	0.00	7.16	1.91	
7	Profit/(Loss) from ordinary activities before exceptional items (5-6)	88.27	175.97	264.24	323.61	423.02	
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	
9	Profit/(Loss) from ordinary activities before tax (7+8)	88.27	175.97	264.24	323.61	423.02	
10	Tax Expenses						
	Current Tax	45.30	0.00	45.30	2.00	0.00	
	Deferred Tax	(2.41)	0.00	(2.41)	0.00	0.00	
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	45.88	175.97	221.35	321.61	423.02	
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00	95.46	
13	Net Profit/(Loss) for the period (11+12)	45.88	175.97	221.35	321.61	518.48	
14	Paid-Up equity share capital (Face Value Rs.10 per share)	1323.18	1323.18	1323.18	1323.18	1323.18	
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]	0.00	0.00	0.00	0.00	10582.00	
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised)						
	(a) Basic	0.34	1.33	1.67	2.43	3.20	
	(b) Diluted	0.34	1.31	1.67	2.43	3.15	
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised)						
	(a) Basic	0.34	1.33	1.67	2.43	2.48	
	(b) Diluted	0.34	1.31	1.67	2.21	2.44	



PART II

Particulars	9/30/2013	9/30/2012	9/30/2013	9/30/2012	9/30/2013	9/30/2012	3/31/2013
A PARTICULARS OF SHAREHOLDING							
1 Public shareholding							
a) Number of shares	4697655	4706393	4706393	4706393	4697655	4706393	4706393
b) Percentage of shareholding	35.50	35.57	35.57	35.57	35.50	35.57	35.57
2 Promoters and Promoter Group Shareholding **							
a) Pledge / Encumbered							
Number of shares							
Percentage of shares (as a % of the total shareholding of promoter and promoter group)							
Percentage of shares (as a % of the total share capital of the company)							
b) Non-encumbered							
Number of shares	8534173	8525435	8525435	8525435	8534173	8525435	8525435
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100	100	100
Percentage of shares (as a % of the total share capital of the company)	64.50	64.43	64.43	64.43	64.50	64.43	64.43

B INVESTOR COMPLAINTS



Pending at the beginning of the Quarter	NIL
Received during the quarter	NIL
Disposed off during the quarter	NIL
Remaining unresolved at the end of the quarter	NIL

Notes:

- The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 14th November, 2013
- During the quarter, the company has operated only in one segment i.e. Pharmaceuticals.
- The figures for the corresponding previous periods have been restated/re-grouped, wherever necessary, to make them comparable with the current agreement with the stock exchanges.
- The Auditors of the Company have Reviewed the Financial Results for the quarter ended 30th September, 2013 in accordance with clause 41 of listing agreement with the stock exchanges.

Place : Mumbai

Date: 14th November 2013



KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF ASSETS AND LIABILITIES

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

	Rs. In Lacs	
	Unaudited	Audited
	As at 30th Sept 2013	As at 31st March 2013
Particulars		
EQUITY AND LIABILITIES		
Shareholders Funds		
(a) Share Capital	1,323.18	1,323.18
(b) Reserve and Surplus	10,803.35	10,581.99
Sub-total - Shareholders' Funds	12,126.53	11,905.17
Non-current liabilities		
(a) Deferred tax liabilities (net)	23.02	25.43
(b) Long term provisions	124.90	37.03
Sub Total-Non- current liabilities	147.92	62.46
Current liabilities		
(a) Trade Payables	275.64	1,347.77
(b) Other current liabilities	2,687.15	326.70
(c) Short- term provisions	290.85	36.30
Sub Total- current liabilities	3,253.64	1,710.77
TOTAL- EQUITY AND LIABILITIES	15,528.09	13,678.40
ASSETS		
Non-current assets		
(a) Fixed Assets	843.24	887.38
(b) Non-current investments	119.60	71.59
(c) Long-term loans and advances	0.00	111.83
Sub Total-Non- current assets	962.84	1,070.80
Current assets		
(a) Current investments	4,142.91	10,827.71
(b) Inventories	133.78	153.92
(c) Trade receivables	862.36	1,239.79
(d) Cash and cash equivalents	196.34	294.07
(e) Short-term loans and advances	9,090.65	29.80
(f) Other current assets	139.21	62.31
Sub Total- current assets	14,565.25	12,607.60
TOTAL ASSETS	15,528.09	13,678.40

For and on Behalf of the Board

MUKUND MEHTA
(Managing Director)

Place : Mumbai

Date: 14th November 2013

